Cellectis S.A. (NASDAQ:CLLS) Sees Significant Growth in Short Interest

Cellectis S.A. (NASDAQ:CLLS) was the recipient of a large increase in short interest in the month of January. As of January 31st, there was short interest totalling 221,300 shares, an increase of 34.0% from the January 15th total of 165,200 shares. Based on an average trading volume of 139,900 shares, the days-to-cover ratio is presently 1.6 days.

Cellectis Trading Up 1.3 %

CLLS traded up $0.02 on Friday, hitting $1.55. 77,558 shares of the stock traded hands, compared to its average volume of 167,729. The company has a current ratio of 1.78, a quick ratio of 1.78 and a debt-to-equity ratio of 0.48. The business has a fifty day moving average price of $1.66 and a two-hundred day moving average price of $1.93. Cellectis has a 52 week low of $1.41 and a 52 week high of $3.38.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Cellectis stock. Wells Fargo & Company MN grew its stake in Cellectis S.A. (NASDAQ:CLLS) by 103.4% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 24,590 shares of the biotechnology company’s stock after purchasing an additional 12,500 shares during the quarter. Wells Fargo & Company MN’s holdings in Cellectis were worth $44,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 63.90% of the company’s stock.

Analyst Ratings Changes

CLLS has been the topic of several research analyst reports. StockNews.com initiated coverage on Cellectis in a research report on Friday, January 24th. They set a “buy” rating on the stock. Barclays decreased their target price on Cellectis from $7.00 to $5.00 and set an “overweight” rating for the company in a research report on Tuesday, November 5th.

About Cellectis

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.